(TheNewswire)
Winnipeg – TheNewswire- June 27, 2024 - Cytophage Technologies Ltd.( TSXV:CYTO ) (“ Cytophage ” or the “ Company ”), the only publicly traded phage companythat is focused on bacteriophage solutions for both animal health andhuman health, is pleased to report the results of its annual generalmeeting (the " AGM ") of shareholders held on June 25,2024 in Toronto, ON.
Atthe AGM, shareholders elected the slate of directors proposed in theManagement Information Circular dated May 24, 2024 (the“ Circular ”) which was sent to shareholders inconnection with the AGM, including new member Michael Sorkin, a 30+year commercial sales andmarketing veteran of medical devices and servicesaround the world, further expanding the Company’s expertise ingetting products to market.
Chairman of the Board Harold Wolkin commented: “Since going publicin early February, we have managed to build a high-calibre board thatI am proud to chair. On behalf of all directors, I welcome Michael toour ranks, and I look forward to incorporating the commercializationexpertise he brings to the table. Andy Hurley decided not to stand forre-election to the board, and I would like to thank him for hisinsights and contributions to the organization.”
Michael Sorkin brings invaluable global commercialexperience in medical devices and services, having launched anddeveloped diverse and inclusive organizations for KMT Medical,Hollister, and Boston Scientific. Since 1995, Michael has led and hashad full P&L responsibility for country and regional commercialoperations while living in Europe, Australia/NZ, Japan, Asia, and theUS. Most recently, as Managing Director of KMT Medical, Chair of theKMT Management Board, and member of the Executive Committee, Michaelhad full P&L responsibility for a 10-country, multi-national homecare business.
Prior to KMT, Michael was Chief Commercial Officer ofHollister, a $1B commercial organization, where revenue and profitsgrew significantly through the commercialization of groundbreaking newproducts and by improving leadership and sales and marketingpractices. Michael was previously VP Europe for Hollister, and beforethat, VP of Asia and Latin America. Michael was promoted to CorporateOfficer in 2016 and to Executive Vice President in 2018. Previously,during 22 years at Boston Scientific, Michael led rapidly growingbusinesses in Europe and Asia ranging from start up to $400M.
AGM Voting Results
Atotal of 14,550,162 common shares were voted at the AGM either inperson or by proxy, representing 26.068% of the total issued andoutstanding common shares of the Company.
All matters presented to the shareholders for approval at the AGMwere approved by shareholders, including:
(1) Fixing the number of directors to be elected at eight (8)persons and electing Harold Wolkin, Dr. Steven Theriault, RobertGabor, KC, Dr. Shantha Kodihalli, Will Ollerhead, Michael D. Cochrane,John Snisarenko and Michael Sorkin as directors for the ensuingyear;
(2) Re-appointing McGovernHurley LLP as auditors for the Company for theensuing year and authorizing the Directors to fix the auditors’remuneration; and
(3) approving the Company’s new form of Equity Incentive Plan,which plan was attached to the Circular as Schedule“A”.
The Report of Voting Results has been filed under the SEDAR+ profileat www.sedarplus.ca .
Cytophage will hold an investor call on July 9, 2024 at 11:00am ETvia Zoom to discuss recent developments in the human health and animalhealth portfolios. Below is the Zoom link: Cytophage InvestorsMeeting July 9 2024.
For further information pleasecontact:
Heather Medwick
Chief Operating Officer
heather@cytophage.com
431 388 8873
Cytophage Investor Alerts: https://cytophage.com/subscribe/
About Cytophage Technologies
Cytophage Technologies ( TSXV:CYTO ) is apioneering biotechnology company dedicated to bacteriophage research,product development and commercialization. Committed to addressing theglobal challenge of antibiotic resistance, Cytophage advancesinnovative products that harness the power of bacteriophages to combatbacterial infections affecting human health, animal health, and foodsecurity.
Cautionary Statement onForward-Looking Information
This news release contains “forward-lookinginformation” and “forward-looking statements” (collectively,“forward-looking statements”) within the meaning of the applicableCanadian securities legislation. All statements, other than statementsof historical fact, are forward-looking statements and are based onexpectations, estimates and projections as at the date of this newsrelease. Any statement that involves discussions with respect topredictions, expectations, beliefs, plans, projections, objectives,assumptions, future events or performance (often but not always usingphrases such as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors whichmay cause the actual results, performance or achievements of Cytophageto be materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are
described under the caption “Risk Factors” inCytophage’s Filing Statement dated January 30, 2024, which isavailable for view on SEDAR+ at www.sedarplus.ca. These risks includebut are not limited to, the risks associated with the bacteriophageindustry, such as operational risks in development or capitalexpenditures, the uncertainty of extensive regulatory approvalrequirements, government regulations, protection of intellectualproperty, product liability and rapid technological advancements.Forward-looking statements contained herein are made as of the date ofthis press release, and Cytophage disclaims, other than as required bylaw, any obligation to update any forward-looking statements whetheras a result of new information, results, future events, circumstances,or if management’s estimates or opinions should change, orotherwise. There can be no assurance that forward-looking statementswill prove to be accurate, as actual results and future events coulddiffer materially from those anticipated in such statements.Accordingly, the reader is cautioned not to place undue reliance onforward-looking statements.
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease.
Copyright (c) 2024 TheNewswire - All rights reserved.